While we, after multiple rounds of optimization, succeeded to achieve an acceptable and consistent knockdown efficiency for both FKBP11 and PPIB in the hybridoma cell line, we failed doing so for the plasma cell myeloma cell line JK-6L. This evidence concerns the gene PPIB and plasma cell myeloma.